Teleflex (NYSE:TFX) Stock Rating Lowered by Raymond James

Teleflex (NYSE:TFX) was downgraded by Raymond James from an “outperform” rating to a “market perform” rating in a report issued on Friday,Briefing.com Automated Import reports.

Several other equities research analysts have also recently weighed in on TFX. StockNews.com raised shares of Teleflex from a “hold” rating to a “buy” rating in a research report on Thursday, November 28th. Needham & Company LLC reaffirmed a “hold” rating on shares of Teleflex in a research note on Monday, December 16th. Mizuho decreased their target price on shares of Teleflex from $275.00 to $250.00 and set a “neutral” rating for the company in a research report on Friday, November 1st. Piper Sandler restated a “neutral” rating and set a $140.00 price target (down from $255.00) on shares of Teleflex in a report on Friday. Finally, Royal Bank of Canada cut their price target on Teleflex from $275.00 to $245.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Seven research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $207.00.

Teleflex Stock Performance

Shares of TFX opened at $138.99 on Friday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.39 and a current ratio of 2.42. Teleflex has a twelve month low of $135.95 and a twelve month high of $249.90. The firm’s 50 day moving average price is $176.35 and its two-hundred day moving average price is $205.70. The firm has a market cap of $6.46 billion, a P/E ratio of 27.63, a PEG ratio of 1.73 and a beta of 1.16.

Teleflex (NYSE:TFX) last issued its earnings results on Thursday, February 27th. The medical technology company reported $3.89 earnings per share for the quarter, topping analysts’ consensus estimates of $3.86 by $0.03. Teleflex had a net margin of 7.85% and a return on equity of 14.19%. The business had revenue of $795.40 million for the quarter, compared to the consensus estimate of $813.24 million. On average, analysts forecast that Teleflex will post 13.98 EPS for the current fiscal year.

Hedge Funds Weigh In On Teleflex

A number of large investors have recently bought and sold shares of the stock. Avior Wealth Management LLC increased its stake in shares of Teleflex by 190.6% during the third quarter. Avior Wealth Management LLC now owns 154 shares of the medical technology company’s stock valued at $38,000 after buying an additional 101 shares during the period. Ashton Thomas Securities LLC bought a new stake in Teleflex in the third quarter worth $40,000. Headlands Technologies LLC bought a new position in shares of Teleflex during the fourth quarter valued at $29,000. True Wealth Design LLC lifted its holdings in shares of Teleflex by 16,600.0% during the third quarter. True Wealth Design LLC now owns 167 shares of the medical technology company’s stock valued at $41,000 after purchasing an additional 166 shares in the last quarter. Finally, Capital Performance Advisors LLP bought a new position in shares of Teleflex during the third quarter valued at $54,000. 95.62% of the stock is owned by hedge funds and other institutional investors.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.